Sign Up Today and Learn More About BioAge Labs Stock
Invest in or calculate the value of your shares in BioAge Labs or other pre-IPO companies through EquityZen's platform.
BioAge Labs Stock (BILB)
BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.
About BioAge Labs Stock
Founded
2015
Headquarters
Richmond, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
BioAge Labs Press Mentions
Stay in the know about the latest news on BioAge Labs
Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial
medcitynews • Apr 14, 2025
The Future of Health Is Here: Is Latin America Ready to Lead?
mexicobusiness • Mar 27, 2025
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
biospace • Mar 21, 2025
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
globenewswire • Mar 20, 2025
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
morningstar • Mar 11, 2025
BioAge Labs Management
Leadership team at BioAge Labs
CEO & Co-Founder
Kristen Fortney
Co-founder and COO
Eric Morgen
Join now and verify your accreditation status to gain access to:
- BioAge Labs Current Valuation
- BioAge Labs Stock Price
- BioAge Labs Management
- Available deals in BioAge Labs and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- BioAge Labs Cap Table and Funding History by Share Class and Liquidity Preferences
- BioAge Labs Revenue and Financials
- BioAge Labs Highlights
- BioAge Labs Business Model
- BioAge Labs Risk Factors
- BioAge Labs Research Report from SACRA Research
Trading BioAge Labs Stock
How to invest in BioAge Labs stock?
Accredited investors can buy pre-IPO stock in companies like BioAge Labs through EquityZen funds. These investments are made available by existing BioAge Labs shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell BioAge Labs stock?
Shareholders can sell their BioAge Labs stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
